ASPIRE-ing to answer the Triplet question! With Rana McKay and Deepak Kilari

The trial they said would never be done! Huge congrats to the Alliance for Clinical Trials in Oncology who have recently opened the ASPIRE trial, a phase III randomised trial of ADT + apalutamide (doublet), vs ADT + apalutamide + docetaxel chemotherapy (triplet) for men with mHSPC. 1200 men will be recruited from more than 300 sites across the US with many sites already open and recruiting. This is the key trial which will answer the question of whether there is an overall survival benefit of adding chemo to the ADT/ARPI doublet which we all agree is standard of care.

We chat with study chair Dr Deepak Kilari (Medical College of Wisconsin) and Dr Rana McKay (University of California San Diego), and learn all about the rationale for ASPIRE, the study design, and the novel genomic stratification factors. Your usual hosts are Renu Eapen and (chemo-sceptic) Declan Murphy!

This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson Pharmaceuticals.

Links:

Alliance website with study details

Urology Times coverage

Clinical Trials registration

Also available as an audio podcast - just search GU Cast wherever you get your podcasts, or play directly below